To evaluate the clinical relevance of the NSCLC-induced T cell mal-differentiation, healthy CD4+ T cells were pre-incubated with patient-derived primary NSCLC cells and then activated with anti-CD3/CD28 beads for 4 days (Fig. S2E). This evidence concerns the gene CD28 and non-small cell lung carcinoma.